已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Giant Cell Tumor of the Extremity

刮除术 医学 骨巨细胞瘤 巨细胞 外科 巨细胞瘤 骨移植 病理
作者
Xiaohui Niu,Qing Zhang,Hao Lin,Yi Ding,Yuan Li,Hairong Xu,Weifeng Liu
出处
期刊:Journal of Bone and Joint Surgery, American Volume [Wolters Kluwer]
卷期号:94 (5): 461-467 被引量:188
标识
DOI:10.2106/jbjs.j.01922
摘要

Background: There are no recent reports of giant cell tumors of bone in a large series of Chinese people. The present study was designed to review the epidemiological characteristics and outcomes of surgical management in a large series of Chinese patients with giant cell tumor of an extremity, treated at a single institution. Methods: The records and images of 621 patients in whom a benign giant cell tumor in an extremity was treated between 1989 and 2009 were reviewed retrospectively. There were 359 male and 262 female patients. The mean age at diagnosis was 31.4 years (range, eleven to seventy-one years). Sixty-six percent of the giant cell tumors were localized around the knee. Surgical treatments primarily included curettage, extensive curettage, and resection. The median duration of follow-up was forty-nine months (range, eighteen to 256 months). Results: Giant cell tumor accounted for 13.7% of all primary bone tumors treated at our institution. Multivariate Cox regression analysis indicated that the only variable that contributed to recurrence-free survival was the type of surgical treatment. The local recurrence rate after extensive curettage was 8.6%, which was significantly lower than the 56.1% recurrence rate after curettage alone. Bone-grafting did not affect local tumor control after extensive curettage; the local recurrence rate was 11.1% if bone graft was used. Recurrent giant cell tumor can be treated by further curettage or resection, with acceptable re-recurrence rates of 6.7% and 9.3% respectively. The Musculoskeletal Tumor Society Score for patients treated with extensive curettage was 92.6%, which was significantly higher than that for patients treated with resection. Twenty-one (3.4%) of the 621 patients developed benign pulmonary metastasis, with a favorable outcome, and three patients presented with multifocal giant cell tumors. Conclusions: The incidence of giant cell tumor in the Chinese population may be higher than that in Western countries, and it has a male predilection. The results of the present study suggest that extensive curettage provides favorable local control and satisfactory functional outcomes. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
干净的琦应助liangliang采纳,获得30
1秒前
2秒前
3秒前
饱满不愁完成签到,获得积分10
3秒前
子车采蓝发布了新的文献求助10
4秒前
Jocelyn完成签到,获得积分10
4秒前
4秒前
Glileo完成签到,获得积分10
5秒前
Akim应助enn采纳,获得10
5秒前
qqqq发布了新的文献求助10
6秒前
eternity发布了新的文献求助10
7秒前
9秒前
pcr163应助LDH采纳,获得500
10秒前
晚随月完成签到 ,获得积分10
10秒前
科研通AI6.2应助辛勤亦丝采纳,获得10
11秒前
小磊发布了新的文献求助10
12秒前
15秒前
幽默梦之完成签到 ,获得积分10
17秒前
qingshu应助冷傲迎梦采纳,获得10
18秒前
18秒前
ji发布了新的文献求助10
18秒前
科研通AI6.2应助smartmorefit采纳,获得10
23秒前
cc2004bj应助lililiwithin采纳,获得10
24秒前
科研通AI6.2应助12采纳,获得10
25秒前
25秒前
李健应助小磊采纳,获得10
27秒前
qizhixu发布了新的文献求助10
29秒前
smartmorefit完成签到,获得积分20
30秒前
hzy完成签到 ,获得积分10
35秒前
在水一方应助漫漫楚威风采纳,获得10
36秒前
潇洒的以柳完成签到 ,获得积分10
41秒前
baihehuakai完成签到 ,获得积分10
43秒前
45秒前
sqb完成签到,获得积分10
46秒前
46秒前
zhangyi发布了新的文献求助10
50秒前
53秒前
科研通AI6.2应助yy采纳,获得10
56秒前
orixero应助子车采蓝采纳,获得10
57秒前
57秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Adhesion Science: Principles & Practice 800
Signals, Systems, and Signal Processing 610
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6522497
求助须知:如何正确求助?哪些是违规求助? 8315739
关于积分的说明 17790940
捐赠科研通 5624670
什么是DOI,文献DOI怎么找? 2927969
邀请新用户注册赠送积分活动 1904739
关于科研通互助平台的介绍 1764766